Risk of suicide during treatment with venlafaxine, italopram, fluoxetine, and dothiepin : retrospective cohort study by Rubino, Annalisa et al.
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
access to the published version may require a subscription. 
 
Author(s): Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, 
Scott Weich and Elizabeth Andrews 
Article Title: Risk of suicide during treatment with venlafaxine, italopram, 
fluoxetine, and dothiepin: retrospective cohort study 
Year of publication: 2006 
Link to published 
version:http://dx.doi.org/10.1136/bmj.39041.445104.BE  
Publisher statement: None 
 
doi:10.1136/bmj.39041.445104.BE 
 2007;334;242; originally published online 12 Dec 2006; BMJ
  
Elizabeth Andrews 
Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich and
  
 dothiepin: retrospective cohort study
venlafaxine, citalopram, fluoxetine, and 
Risk of suicide during treatment with
 http://bmj.com/cgi/content/full/334/7587/242
Updated information and services can be found at: 
 These include:
Data supplement
 http://bmj.com/cgi/content/full/bmj.39041.445104.BE/DC1
 "Appendix (pdf)"
 References
 http://bmj.com/cgi/content/full/334/7587/242#otherarticles
3 online articles that cite this article can be accessed at: 
  
 http://bmj.com/cgi/content/full/334/7587/242#BIBL
This article cites 21 articles, 10 of which can be accessed free at: 
Rapid responses
 http://bmj.com/cgi/eletter-submit/334/7587/242
You can respond to this article at: 
  
 http://bmj.com/cgi/content/full/334/7587/242#responses
for free at: 
12 rapid responses have been posted to this article, which you can access
 service
Email alerting
box at the top left of the article 
Receive free email alerts when new articles cite this article - sign up in the
Topic collections
 (954 articles) Suicide (public health) 
 (2206 articles) Drugs: musculoskeletal and joint diseases 
 (954 articles) Suicide (psychiatry) 
 (6835 articles) Epidemiologic studies 
  
Articles on similar topics can be found in the following collections 
 Notes   
To order reprints follow the "Request Permissions" link in the navigation box 
 http://resources.bmj.com/bmj/subscribers
 go to: BMJTo subscribe to 
 on 23 October 2008 bmj.comDownloaded from 
Research
Risk of suicide during treatment with venlafaxine, citalopram,
fluoxetine, and dothiepin: retrospective cohort study
Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich, Elizabeth Andrews
Abstract
Objective To compare the risk of suicide in adults using the
antidepressant venlafaxine compared with citalopram,
fluoxetine, and dothiepin.
Design Retrospective cohort study.
Setting UK General Practice Research Database.
Participants 219 088 patients, aged 18-89 years, who were
prescribed venlafaxine, citalopram, fluoxetine, or dothiepin
from 1995 to 2005.
Main outcome measures Completed suicide and attempted
suicide.
Results Venlafaxine users had a higher burden of risk factors
for suicide, including previous suicide attempts and proxies for
severe depression or depression that was difficult to treat. In the
analysis for completed suicides, unadjusted and adjusted hazard
ratios for venlafaxine compared with citalopram were 2.44
(95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80),
for venlafaxine compared with fluoxetine were 2.85 (1.37 to
5.94) and 1.63 (0.74 to 3.59), and for venlafaxine compared
with dothiepin were 2.54 (1.07 to 6.02) and 1.31 (0.53 to 3.25).
Compared with other study drugs, venlafaxine was also
associated with an increased risk of attempted suicide, but
adjustment for measured confounders substantially reduced the
hazard ratios.
Conclusions Venlafaxine use was consistently associated with
higher risk of suicide compared with citalopram, fluoxetine, and
dothiepin. Venlafaxine users had a higher burden of suicide risk
factors, however, and adjustment for measured confounders
substantially reduced the excess risks. Since the secondary data
used in this analysis allowed only indirect and partial
measurements of potential confounders, it is possible that
residual confounding explains much, if not all, of the observed
excess risk.
Introduction
In late 2004 drug regulatory agencies in the United States and
Europe warned that adults being treated with antidepressants
should be monitored closely for worsening of depression and for
increased suicidal thinking or behaviour, particularly at the start
of treatment or when changing doses.1 2 This action was largely
in response to meta-analyses of randomised controlled trials in
patients younger than 19, which found that selective serotonin
reuptake inhibitors and other newer antidepressants may
increase the risk of suicidal thinking and self harm.3 4 Three
meta-analyses of clinical trials in adults, however, found no
increased risk of suicide associated with antidepressants
compared with placebo.5–7 Observational studies have not found
any substantial and consistent differences in suicide risk across
commonly prescribed selective serotonin reuptake inhibitors
and tricyclic antidepressants.8–13 No observational studies have,
however, quantified a potential association between treatment
with venlafaxine and risk of suicide.
Venlafaxine, a serotonin and noradrenaline reuptake inhibi-
tor, is an antidepressant indicated for the treatment of
depression and anxiety. In clinical practice it has often been pre-
scribed for patients unresponsive to selective serotonin reuptake
inhibitors or tricyclic antidepressants.14 15 A recent observational
study showed that patients treated with venlafaxine had a higher
prevalence of risk factors for suicide, including previous suicide
attempt, admission to hospital for depression, and diagnoses of
schizophrenia and bipolar disorder than patients prescribed
selective serotonin reuptake inhibitors.16 We assessed whether
the risk of completed and attempted suicide in patients
prescribed venlafaxine differs from that in patients prescribed
other antidepressants.
We carried out a retrospective cohort study in the general
practice research database, which collects electronic medical
records within UK primary care.17 18 Tominimise confounding by
severity of disease, we selected the selective serotonin reuptake
inhibitor citalopram as a comparator antidepressant. As
citalopram and venlafaxine were introduced in the same year, we
assumed that doctors would preferentially prescribe both agents
to patients who were unresponsive to previously available thera-
pies19 and presumably had similar background risks of suicide.
We also selected fluoxetine and dothiepin because they are the
most commonly prescribed drugs within their respective classes.
Methods
We selected patients on the basis of an incident prescription (that
is, first ever prescription in the patient’s medical record) for ven-
lafaxine, citalopram, fluoxetine, or dothiepin during the study
period 1995 to 2005. After we applied the quality control criteria
for the general practice research database, we restricted the study
population to patients aged 18 to 89 years at the time of incident
prescription for any study drug, and with a record of depression
or anxiety. To characterise medical history, we selected patients
with one or more years of follow-up within the database before
the incident prescription.
Patients were followed from their incident prescription date
until the earliest of completed suicide or first attempted suicide,
the end of the study period, or the end of the patient’s record.We
Operational definitions and coding for suicides are on bmj.com
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censored follow-up time during periods of no use of any study
drug.
Outcome measures
We defined two end points: completed suicide and the first
attempted suicide during the study period, including completed
suicides.
Completed suicide was defined by any coding for death asso-
ciated with mention of suicide in free text entries or by a code for
suicide in the medical record accompanied by a statement of
death in the administrative record (30 days either way). For the
completed suicide analysis we included patients with records of
attempted suicide during the study period.
Attempted suicides were identified by a code for suicide
attempts. We excluded records that at the review of free text
notes did not seem to represent attempted suicide—for example,
unintentional overdose or self harm without suicidal intent (see
bmj.com).
Exposure to study drugs
We assumed that exposure to any study drug began on the day
after the prescription date and extended to 14 days after the
imputed end of the prescription, based on number of pills
supplied and dosing instructions. If there was no gap between
the imputed end of a first prescription plus 14 days and the date
of the subsequent prescription for the same drug, then we
concatenated the two periods to represent a continuous episode
of treatment. We concatenated subsequent prescriptions
similarly. Each participant could experience multiple episodes of
treatment for one or more study drugs.
When prescription records indicated concomitant use of
multiple antidepressants, including non-study antidepressants,
we assumed there was a switch in therapy. When switching
therapy participants could have been exposed to more than one
antidepressant for a short period, and we accounted for this
“overlap with other antidepressant” in the stratified and
multivariable analyses. We also examined the effect of allocating
usage time for only seven days after the imputed end of a
prescription.
Analysis covariates
To account for potential confounders we identified known risk
factors for suicide, including the severity of underlying disease.
The confounders we considered were age, sex, diagnosis for
study inclusion (depression or anxiety, or both), suicide attempts,
major life events, lifestyle factors, family history of psychiatric
morbidity, psychotropic comedications, and psychiatric comor-
bidities. Age was categorised into the groups 18-29, 30-59, and
60 or more years. We also evaluated chronic and disabling non-
psychiatric morbidities that are known to be associated with
onset or worsening of depression. We estimated severity of
depression and depression that was resistant to treatment using
proxies such as admission to hospital and referrals to specialist
mental health services, history of antidepressant treatment, anti-
depressant multitherapy, and number of other previous
antidepressants.We also used an initial prescription of 14 days or
less as a proxy for clinician perceived risk of suicide. Because the
first 30 days of treatment with antidepressants have been associ-
ated with a higher risk of suicide,10 we coded this period
separately.
At the start of each treatment episode we reassessed
confounding factors that could change throughout follow-up
(for example, psychotropic therapy).We derived confounders for
any time and for one month, one year, and ever before an
episode of treatment, as appropriate.
Statistical analysis
For each drug group we calculated the incidence rate (95% con-
fidence intervals) for completed suicide and first attempted
suicide by dividing the number of outcomes by the total person
time of use of each drug (person years at risk). We evaluated the
potential confounding effect of each covariate by comparing
unadjusted and adjusted incidence rate ratios using Mantel-
Haenszel methods.
For each outcome we built a time dependent Cox hazards
regression model. Follow-up time was linked to calendar time.
Time zero was set at 1 January 1995. Patients could contribute
usage time to more than one treatment. To avoid saturation of
the statistical model in the completed suicide analysis we limited
the analysis covariates to age, sex, age-sex interaction, overlap
with other antidepressants, and the 10 confounders associated
with the largest changes of the adjusted incidence rate ratio of
venlafaxine with each comparator. This resulted in 24 analysis
covariates because we introduced those confounders identified
in more than one paired comparison (for example, venlafaxine
versus citalopram, venlafaxine versus fluoxetine, and venlafaxine
versus dothiepin) only once in the model. The larger number of
outcomes in the attempted suicide analysis allowed us to include
in the model all the variables that modified the adjusted
incidence rate ratios. We estimated hazard ratios (95%
confidence intervals) for each treatment comparison and for
each potential confounder in the model. All analyses were
carried out using SAS for UNIX software (version 9.1).
Results
Overall, 219 088 patients aged 18-89 years who were prescribed
venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to
2005 were identified from the general practice research
database. The distribution of the population characteristics
across drug groups and analysis covariates used in the
completed and the attempted suicide analyses were similar. Table
1 provides data from the completed suicide analysis only.
Distributions of age and sex were consistent across drug
groups (table 1). Most patients (90.5%, n = 198 231) had a
diagnosis of depression as opposed to anxiety. About 25% of
patients had both diagnoses, and this proportion was higher
among patients treated with venlafaxine (35.4%, n = 7725) than
among those treated with fluoxetine (22.0% n = 20 893),
citalopram (27.3%, n = 16 073), or dothiepin (23.9%, n = 10 387).
Patients prescribed venlafaxine also showed signs of more severe
or difficult to treat depression. For instance, history of other anti-
depressant therapy, history of antidepressant multitherapy, and
history of treatment with three or more antidepressants were
more common among patients treated with venlafaxine (table 1).
Furthermore, proxies of depression severity, such as admission
to hospital for psychiatric disorders and referral to specialist
mental health care, were more common among those prescribed
venlafaxine than those prescribed comparator drugs (table 1).
Previous attempted suicide was twice as common among venla-
faxine users than among citalopram or fluoxetine users. Other
suicide risk factors, including psychotropic therapy and family
history of psychiatric disorders, were also more common among
venlafaxine users (table 1). Distribution of chronic or incapacitat-
ing morbidities known to be associated with depression did not
differ across drug groups. Similarly, bereavement or marital
problems were equally distributed across groups (table 1).
Incidence rate and hazard ratio
The completed suicide analysis encompassed 54 events over
173 452 person years for use of any study drug, and the first
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attempted suicide analysis encompassed 3060 events over
169 735 person years at risk. The incidence rate of both
completed and first attempted suicide was higher for venlafaxine
treatment than for each comparator treatment (table 2).
Mantel-Haenszel adjusted incidence rate ratios were calcu-
lated for both the completed and the attempted suicide analyses
(data not shown). In both analyses, adjustment for the higher risk
of suicide during the first 30 days of treatment consistently
increased the incidence rate ratio in each comparison. For most
confounders, however, adjustment was associated with a
reduction in the incidence rate ratio. History of antidepressant
therapy, including antidepressant multitherapy and psycho-
tropic therapy, and previous suicide attempts had the strongest
confounding effect on the association between venlafaxine and
completed or attempted suicide.
Unadjusted and adjusted hazard ratios were calculated for
venlafaxine compared with each study drug. The unadjusted risk
of completed suicide was more than twice as high during venla-
faxine treatment. Adjustment for the measured confounders in
the completed suicide models, however, reduced the excess risk
by at least 50% in each paired comparison (table 3). The
unadjusted risk of attempted suicide was also higher during ven-
lafaxine treatment compared with citalopram, fluoxetine, and
dothiepin treatments. The hazard ratio was substantially reduced
after adjustment for measured confounders (table 4).
When the extended time at risk was reduced from 14 to
seven days after the imputed end of a prescription, the adjusted
hazard ratio of venlafaxine compared with citalopram increased
from 1.70 (95% confidence interval 0.76 to 3.80) to 1.87 (0.81 to
4.29) in the completed suicide analysis and from 1.20 (1.07 to
1.34) to 1.23 (1.10 to 1.37) in the attempted suicide analysis, but
such an increase was inconsistent across comparisons (table 5).
Discussion
The antidepressant venlafaxine was associated with a higher risk
of suicide compared with citalopram, fluoxetine, and dothiepin.
Venlafaxine users had a higher burden of risk factors for suicide,
however, and adjustment for measured confounders substan-
tially reduced the excess risks. While these data may reflect a
causal association between venlafaxine use and suicide, given the
substantial attenuation of this association after adjustment for
confounding and the nature of the data, it is possible that
residual confounding could explain much or all of the remaining
risk.
Venlafaxine use in this study population of adults was associ-
ated with markers of severe and difficult to treat depression, with
psychiatric comorbidities, and with previous treatment with psy-
chotropic agents such as antipsychotics and mood stabilisers.16
Admission to hospital for a psychiatric disorder and specialist
care, family history of psychiatric morbidities, and a history of
suicide attempts were also more prevalent in venlafaxine users.
Furthermore, venlafaxine users were twice as likely to have an
overlap prescription for another antidepressant, suggesting
more frequent switching of drugs. Patients may switch
antidepressant drugs owing to failure to achieve the desired
therapeutic effect, suggesting that venlafaxine users had severe
or treatment resistant depression.
Table 1 Frequency distribution of population characteristics by
antidepressant use in completed suicide analysis. Values are percentages
(numbers) unless stated otherwise
Characteristic Venlafaxine Citalopram Fluoxetine Dothiepin
No of participants 37 857 75 749 108 934 54 035
Mean (SD) age (years) 46.2 (16.4) 47.1 (18.0) 43.9 (16.7) 48.6 (7.3)
Men 33.5 (12
671)
30.5 (23
108)
30.6 (33
322)
30.0 (16
212)
No of treatment episodes 89 296 160 189 283 865 125 123
First prescription ≤14 days 9.9 (8872) 7.3 (11 622) 19.7 (55
960)
10.2 (12
751)
Overlap with other
antidepressants
22.4 (19
997)
11.6 (18
554)
8.7 (24 705) 13.4 (16
755)
Exposure during first 30 days
of treatment episode
53.8 (48
036)
59.9 (96
019)
54.8 (155
571)
59.5 (74
408)
Drug history before treatment
episode:
Same antidepressant 61.6 (55
008)
54.3 (87
000)
63.2 (179
492)
60.4 (75
535)
Other antidepressants 90.6 (80
871)
68.7 (109
972)
59.9 (170
077)
62.6 (78
283)
Other antidepressants in
previous year
55.9 (49
960)
32.5 (52
056)
25.8 (73
278)
32.3 (40
428)
History of antidepressant
multitherapy
13.4 (11
933)
7.2 (11 588) 5.8 (16 599) 7.4 (9207)
No of other previous
antidepressants:
0 9.4 (8425) 31.3 (50
217)
40.1 (113
788)
37.4 (46
840)
≥3 40.8 (36
417)
22.9 (36
610)
14.7 (41
753)
17.3 (21
591)
Any psychotropic therapy* in
60 days before treatment
episode
25.8 (23
014)
18.2 (29
162)
13.9 (39
566)
18.5 (23
162)
Suicidal behaviour in year
before treatment episode
1.9 (1737) 0.9 (1423) 0.8 (2213) 0.4 (549)
Admission to hospital for
psychiatric disorders in
month before treatment
episode
1.2 (1098) 0.9 (1403) 0.6 (1825) 0.6 (726)
Psychiatric referral in year
before treatment episode
3.4 (3002) 1.7 (2756) 1.0 (2979) 0.7 (913)
Any psychiatric morbidity† in
year before treatment
episode
76.8 (68
609)
78.4 (125
561)
77.3 (219
540)
69.8 (87
306)
Non-psychiatric morbidity‡ 11.2 (10
036)
11.9 (18
988)
10.3 (29
333)
12.2 (15
279)
Major life events 2.8 (2469) 2.9 (4693) 2.9 (8303) 3.6 (4493)
Lifestyle factors 8.5 (7581) 7.4 (11 830) 5.1 (14 618) 4.5 (5576)
Family history of psychiatric
morbidity
2.1 (1846) 1.5 (2344) 1.1 (2999) 1.0 (1205)
*Mood stabilisers, including carbamazepine, clonazepam, gabapentin, lamotrigine, lithium,
topiramate, valproic acid, antipsychotics, and benzodiazepines.
†Depression, including dysthymia and chronic fatigue syndrome; somatoform disorders (for
example, somatisation disorder and hypochondriasis); eating disorders (anorexia and bulimia
nervosa); anxiety disorders, including phobias (social phobia, agoraphobia, simple phobias),
obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorder; mixed
anxiety depressive disorder; bipolar affective disorder; schizophrenia; substance abuse
disorder and alcohol abuse syndrome; dementia; and personality disorders, including schizoid,
borderline, and antisocial behaviour.
‡Cancer, Parkinson’s disease, multiple sclerosis, diabetes, cirrhosis, myocardial infarction,
stroke, renal failure, respiratory diseases, and arthritis.
Table 2 Unadjusted incidence rate (95% confidence interval) of completed
and first attempted suicides in adults according to antidepressant
Event and antidepressant
No of
patients*
Person years
at risk
No of
events
Incidence rate
(95% CI) per 1000
person years
Completed suicide:
Venlafaxine 37 857 28 087 18 0.64 (0.40 to 1.02)
Citalopram 75 749 45 639 12 0.26 (0.15 to 0.46)
Fluoxetine 108 934 66 636 15 0.23 (0.14 to 0.37)
Dothiepin 54 035 33 090 9 0.27 (0.14 to 0.52)
First attempted suicide:
Venlafaxine 37 132 26 854 715 26.6 (24.7 to 28.7)
Citalopram 75 103 44 788 781 17.4 (16.3 to 18.7)
Fluoxetine 108 474 65 416 1138 17.4 (16.4 to 18.4)
Dothiepin 53 818 32 677 426 13.0 (11.9 to 14.3)
*Patients could contribute person years at risk to more than one antidepressant.
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In our study, suicide rates were consistently higher across
study drugs during the first 30 days of a treatment episode, con-
firming that starting antidepressants is associated with a higher
risk of suicide.8 The study also confirmed that markers for sever-
ity of psychiatric morbidity were associated with an increased risk
of suicide and suicide attempt in each drug group.
Confounding
Pharmacoepidemiological studies are potentially confounded by
indication; factors associated with choice of therapy may also be
risk factors for the study outcome. Although a randomised clini-
cal trial can eliminate such confounding, this design is not feasi-
ble to evaluate such rare outcomes as suicide. The richness of
longitudinal records in the UK general practice research
database allowed us to adjust for many factors associated with
the risk of suicide and with the selection of antidepressant treat-
ment, but it is possible that our adjustment was incomplete. The
ability to control for confounding depends on the accurate
measurement of potential confounders. Even when the sensitiv-
ity and specificity of the confounder measures are 90%, more
than 30% of confounding remains uncontrolled.20 Adjustment
for misclassification of this magnitude would move the point
estimate for the risk of completed suicide for venlafaxine
compared with citalopram from 1.70 to 1.39, and for attempted
suicide from 1.20 to 1.07. We anticipated that data for defining
referrals to mental health care and admission to hospital, as well
as data on prescriptions, were appropriate and comprehensive.
Psychiatric diagnoses, however, may be undiagnosed or misclas-
sified to a noticeable extent. Most notably, severity of disease, a
strong determinant of suicide risk, could only be measured indi-
rectly. Furthermore, recognised risk factors for suicide, such as
hopelessness, impulsivity, and abuse (child, domestic, or
sexual),21–23 unemployment, poverty, social isolation, and suicidal
Table 3 Cox proportional hazard model to estimate risk of completed
suicide after adjustment for measured risk factors and confounders
Analysis covariates Hazard ratio* (95% CI)
Venlafaxine v citalopram 1.70 (0.76 to 3.80); 2.44 (1.12 to5.31)†
Venlafaxine v fluoxetine 1.63 (0.74 to 3.59); 2.85 (1.37 to
5.94)†
Venlafaxine v dothiepin 1.31 (0.53 to 3.25); 2.54 (1.07 to
6.02)†
Men v women 2.15 (0.53 to 8.67)
Age at start of treatment episode:
30-59 v 18-29 0.56 (0.17 to 1.77)
≥60 v 18-29 0.33 (0.07 to 1.51)
Sex-age interaction:
Men aged 30-59 1.83 (0.38 to 8.80)
Men aged ≥60 2.31 (0.32 to 16.47)
Overlap with other antidepressants (yes v no) 0.75 (0.15 to 3.65)
First 30 days of treatment episode (yes v no) 2.85 (1.51 to 5.39)
Duration of first prescription (≤14 v ≥15 days) 1.35 (0.55 to 3.31)
Drug history before treatment episode:
Same antidepressant (yes v no) 0.51 (0.26 to 0.99)
Other antidepressants ever before (yes v no) 0.56 (0.21 to 1.50)
Other antidepressants in year before (yes v no) 2.21 (0.91 to 5.39)
No of other previous antidepressants (3 v 1 or 2) 1.00 (0.48 to 2.09)
History of antidepressant multitherapy (yes v no) 1.40 (0.59 to 3.30)
Suicidal behaviour in year before treatment episode
(yes v no)
7.51 (2.82 to 19.96)
Admission to hospital for psychiatric disorder in
month before treatment episode (yes v no)
2.53 (0.74 to 8.68)
Psychiatric referral in year before treatment episode
(yes v no)
0.99 (0.23 to 4.32)
Psychotropic therapy in 60 days before treatment
episode:
Any psychotropics (yes v no) 1.96 (0.86 to 4.42)
Antipsychotics (yes v no) 2.46 (1.05 to 5.80)
Mood stabilisers (yes v no) 0.71 (0.22 to 2.34)
Any psychiatric morbidity in year before treatment
episode (yes v no)
0.84 (0.39 to 1.82)
Medical history:
Bipolar disorder (yes v no) 4.94 (1.30 to 18.84)
Depression (yes v no) 1.15 (0.34 to 3.86)
Mixed anxiety and depression (yes v no) 0.71 (0.33 to 1.50)
Substance misuse (yes v no) 1.30 (0.54 to 3.13)
*Measures relative risk of completed suicide adjusted for each analysis covariate after
adjustment for all other variables in model, including treatment.
†Unadjusted values.
Table 4 Cox proportional hazard model to estimate risk of attempted suicide
in adults according to antidepressants after adjustment for measured risk
factors and confounders
Analysis covariates Hazard ratio* (95% CI)
Venlafaxine v citalopram 1.20 (1.07 to 1.34); 1.49 (1.34 to1.66)†
Venlafaxine v fluoxetine 1.28 (1.15 to 1.42); 1.68 (1.52 to
1.86)†
Venlafaxine v dothiepin 1.47 (1.29 to 1.68); 2.41 (2.11 to
2.74)†
Men v women 0.98 (0.85 to 1.14)
Age at start of treatment episode:
30-59 v 18-29 0.37 (0.33 to 0.41)
≥60 v 18-29 0.12 (0.10 to 0.14)
Sex-age interaction:
Men aged 30-59 1.18 (0.99 to 1.41)
Men aged ≥60 1.42 (1.04 to 1.93)
Overlap with other antidepressants (yes v no) 1.74 (1.45 to 2.08)
First 30 days of treatment episode (yes v no) 2.08 (1.91 to 2.27)
Duration of first prescription (≤14 v ≥15 days) 1.65 (1.46 to 1.86)
Drug history:
Same antidepressant (yes v no) 0.73 (0.67 to 0.80)
Other antidepressant in year before treatment
episode (yes v no)
1.17 (1.05 to 1.29)
No of previous other antidepressants:
1 or 2 v 0 1.04 (0.93 to 1.16)
3 v 0 1.14 (1.00 to 1.31)
History of antidepressant multitherapy (yes v no) 1.01 (0.88 to 1.16)
Admission to hospital for psychiatric disorders in
month before treatment episode (yes v no)
3.06 (2.48 to 3.77)
Psychiatric referral in year before treatment
episode (yes v no)
1.80 (1.48 to 2.18)
Psychotropic therapy in 60 days before treatment
episode:
Any psychotropics (yes v no) 2.22 (2.01 to 2.46)
Antipsychotics (yes v no) 1.07 (0.93 to 1.22)
Mood stabilisers (yes v no) 0.88 (0.73 to 1.06)
Diagnosis of depression (yes v no) 1.42 (1.05 to 1.91)
Medical history:
Bipolar disorder (yes v no) 1.47 (1.05 to 2.07)
Depression (yes v no) 1.09 (0.74 to 1.59)
Eating disorder (yes v no) 1.71 (1.41 to 2.06)
Personality disorder (yes v no) 1.78 (1.49 to 2.12)
Substance misuse (yes v no) 2.24 (1.96 to 2.57)
Psychiatric morbidity in year before treatment
episode:
Any psychiatric morbidity (yes v no) 1.01 (0.82 to 1.24)
Anxiety (yes v no) 1.11 (1.00 to 1.23)
Depression (yes v no) 1.46 (1.22 to 1.74)
Mixed anxiety and depression (yes v no) 1.00 (0.88 to 1.11)
Substance misuse (yes v no) 1.62 (1.35 to 1.95)
Any health problem before or during treatment
episode (yes v no)
0.72 (0.61 to 0.83)
*Measures relative risk of completed suicide adjusted for each analysis covariate after
adjustment for all other variables in model, including treatment.
†Unadjusted values.
Research
page 4 of 6 BMJ Online First bmj.com
 on 23 October 2008 bmj.comDownloaded from 
ideation, are not routinely recorded in the general practice
research database and could not be accounted for in this analy-
sis.
Adjustment for measured confounders substantially reduced
the excess risk of suicide associated with venlafaxine. As the
amount of residual confounding tends to reflect the overall con-
founding in the data,20 24 adjustment for measured confounding
was unlikely to fully compensate for a potential bias introduced
by systematic channelling of more severely depressed patients
towards venlafaxine treatment. We suspect that correction for
this residual bias could result in further change of the effect esti-
mates towards the null value.
Study strengths and limitations
The major strength of this study was the large study population
and the completeness of longitudinal records for assessment of
drug use and measurement of risk factors. We also confirmed
many of the expected associations with risk factors, such as
markers of depression severity, and suicide risk. As with any ret-
rospective study using secondary data, however, this study had
several limitations, including lack of direct measurement of
disease severity and partial assessment of some variables such as
major life events that are likely to be inconsistently recorded in
the general practice research database. The potential for some
exposure and outcome misclassification should also be
considered.We imputed drug use and time at risk on the basis of
fully comprehensive prescription records from the database.
However, prescribing within the secondary care setting might
have been missing, leading to potential underestimation of drug
use in more severe patients under psychiatric care. To impute
duration of prescriptions and time at risk we made assumptions;
overall compliance with treatments was also assumed. We used a
sensitivity analysis to evaluate whether reducing the duration of
drug use after the imputed end of prescriptions from 14 to seven
days affected the relative risk estimate. Shortening the definition
of time at risk only marginally and inconsistently increased the
relative risk estimates and did not lead to a substantial difference
in study results.
One of the strengths of the general practice research
database is the high quality of information on mortality, includ-
ing cause of death.11 18 None the less, in secondary data cause of
death is associated with somemisclassification, all the more given
the nature of this specific study outcome, since completed
suicide is most often an unwitnessed event and loaded with social
stigma. Although we identified completed suicide in accordance
with procedures previously published and validated10 11 potential
misclassification and under-ascertainment cannot be ruled out.
We would anticipate that misclassification of completed suicides
is less likely among people with most severe depression—that is,
patients taking venlafaxine—who can be expected to be more
closely monitored. Attempted suicide represented a less clearly
defined outcome and non-differential misclassification, which
may bias the relative risk towards the null, could occur.
Conclusions
We found a higher risk of suicide associated with venlafaxine
compared with citalopram, fluoxetine, and dothiepin, which
could reflect a causal association. However, because venlafaxine
was channelled towards patients with more severe and treatment
resistant depression, adjustment for measured risk factors could
have left residual confounding that could explain some or all of
the excess risk associated with venlafaxine.
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Table 5 Unadjusted and adjusted hazard ratios (95% CI) for completed and
attempted suicides for venlafaxine treatment compared with citalopram,
fluoxetine and dothiepin treatment when time at risk included seven or 14
days at imputed end of prescription
Event and
antidepressants
14 days 7 days
Unadjusted
hazard ratio
(95% CI)
Adjusted
hazard ratio
(95% CI)
Unadjusted
hazard ratio
(95% CI)
Adjusted
hazard ratio
(95% CI)
Completed suicide:
Venlafaxine v
citalopram
2.44
(1.12 to 5.31)
1.70
(0.76 to 3.80)
2.56
(1.14 to 5.77)
1.87
(0.81 to 4.29)
Venlafaxine v
fluoxetine
2.85
(1.37 to 5.94)
1.63
(0.74 to 3.59)
3.19
(1.46 to 7.00)
1.87
(0.81 to 4.32)
Venlafaxine v
dothiepin
2.54
(1.07 to 6.02)
1.31
(0.53 to 3.25)
2.37
(0.98 to 5.73)
1.27
(0.51 to 3.18)
Attempted suicide:
Venlafaxine v
citalopram
1.49
(1.34 to 1.66)
1.20
(1.07 to 1.34)
1.52
(1.36 to 1.69)
1.23
(1.10 to 1.37)
Venlafaxine v
fluoxetine
1.68
(1.52 to 1.86)
1.28
(1.15 to 1.42)
1.68
(1.52 to 1.87)
1.28
(1.14 to 1.43)
Venlafaxine v
dothiepin
2.41
(2.11 to 2.74)
1.47
(1.29 to 1.68)
2.38
(2.08 to 2.72)
1.45
(1.27 to 1.67)
What is already known on this topic
The risk of suicide during treatment with commonly
prescribed selective serotonin reuptake inhibitors and
tricyclic antidepressants is similar
The risk with venlafaxine, however, has not been evaluated
in population based studies
What this study adds
Venlafaxine users were more likely to commit or attempt
suicide than patients using citalopram, fluoxetine, or
dothiepin
Venlafaxine users had a higher burden of suicide risk
factors at start of treatment; adjustment for measured
confounders reduced the excess risk
Because residual confounding was possible, the increased
risk of suicide associated with venlafaxine therapy should
not be seen as causal
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